Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veligrotug in chronic thyroid eye disease
NCT06021054Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of veligrotug in thyroid eye disease (TED), sponsored by Viridian Therapeutics. Started Nov 2023; status: completed.
02
Drugs
veligrotug
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06021054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021054.